Last reviewed · How we verify
PE0116
At a glance
| Generic name | PE0116 |
|---|---|
| Also known as | Recombinant Anti-4-1BB Human Monoclonal Antibody Injection |
| Sponsor | Shanghai HyaMab Biotech Co.,Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor (PHASE1, PHASE2)
- PE0116 Injection in Treatment of Patients With Advanced Solid Tumours (PHASE1)
- A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PE0116 CI brief — competitive landscape report
- PE0116 updates RSS · CI watch RSS
- Shanghai HyaMab Biotech Co.,Ltd. portfolio CI